MX2021011007A - Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. - Google Patents

Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.

Info

Publication number
MX2021011007A
MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A
Authority
MX
Mexico
Prior art keywords
drug
complications
diabetes
treat
prevent
Prior art date
Application number
MX2021011007A
Other languages
English (en)
Spanish (es)
Inventor
Keita Shibata
Ryosuke Ryosuke
Terumasa Hashimoto
Koji Nobe
Original Assignee
Univ Showa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Showa filed Critical Univ Showa
Publication of MX2021011007A publication Critical patent/MX2021011007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021011007A 2019-03-12 2020-03-12 Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. MX2021011007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (1)

Publication Number Publication Date
MX2021011007A true MX2021011007A (es) 2022-03-11

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011007A MX2021011007A (es) 2019-03-12 2020-03-12 Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.

Country Status (15)

Country Link
US (1) US20220218664A1 (en, 2012)
EP (1) EP3939659A4 (en, 2012)
JP (1) JPWO2020184691A1 (en, 2012)
KR (1) KR20220009371A (en, 2012)
CN (1) CN114126711A (en, 2012)
AU (1) AU2020238177A1 (en, 2012)
BR (1) BR112021018084A8 (en, 2012)
CA (1) CA3133204A1 (en, 2012)
CL (1) CL2021002373A1 (en, 2012)
EA (1) EA202192483A1 (en, 2012)
IL (1) IL286289A (en, 2012)
MX (1) MX2021011007A (en, 2012)
PE (1) PE20220333A1 (en, 2012)
SG (1) SG11202109982YA (en, 2012)
WO (1) WO2020184691A1 (en, 2012)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
EP4293028A4 (en) * 2021-02-10 2024-10-30 Shanghai Senhui Medicine Co., Ltd. Smtp-7 derivative and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ｎｇｆ作用増強因子
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
EP1944027A4 (en) 2005-10-06 2009-08-19 Univ Tokyo Nat Univ Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD OF MANUFACTURE THEREOF
JP4395540B2 (ja) 2006-03-27 2010-01-13 農工大ティー・エル・オー株式会社 トリプレニルフェノール化合物及びトリプレニルフェノール化合物の製造方法並びに、血栓溶解促進剤
WO2010110026A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物
EP2452679B1 (en) * 2009-07-06 2014-05-28 National University Corporation Tokyo University Of Agriculture and Technology Triprenylphenolic cytoprotective agent
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
WO2012115209A1 (ja) * 2011-02-24 2012-08-30 国立大学法人東京農工大学 可溶性エポキシドハイドロラーゼ阻害剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Also Published As

Publication number Publication date
JPWO2020184691A1 (en, 2012) 2020-09-17
EP3939659A4 (en) 2022-12-21
US20220218664A1 (en) 2022-07-14
WO2020184691A1 (ja) 2020-09-17
KR20220009371A (ko) 2022-01-24
AU2020238177A1 (en) 2021-11-04
EA202192483A1 (ru) 2021-12-24
IL286289A (en) 2021-10-31
EP3939659A1 (en) 2022-01-19
BR112021018084A8 (pt) 2022-10-04
CA3133204A1 (en) 2020-09-17
SG11202109982YA (en) 2021-10-28
CL2021002373A1 (es) 2022-06-17
PE20220333A1 (es) 2022-03-14
BR112021018084A2 (en, 2012) 2021-12-21
CN114126711A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UY37831A (es) Nuevos derivados de quinolina
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CO2020001242A2 (es) Dihidrooxadiazinonas
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
MX2021012750A (es) Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
MX385269B (es) Compuesto de sulfonamida o sal del mismo.
CO2021012559A2 (es) Compuestos macrocíclicos como agonistas de sting
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
MX2021011007A (es) Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.
UY35785A (es) Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)
MX390507B (es) Compuestos de amida y su uso.
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
AR109406A1 (es) Compuesto de 1-fenil-3-carbamoilurea y su uso